Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) EBITDA (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed EBITDA for 6 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 316.34% year-over-year to $11.1 million, compared with a TTM value of $554000.0 through Dec 2025, up 101.01%, and an annual FY2025 reading of $554000.0, up 101.01% over the prior year.
  • EBITDA was $11.1 million for Q4 2025 at Xeris Biopharma Holdings, up from $620000.0 in the prior quarter.
  • Across five years, EBITDA topped out at $11.1 million in Q4 2025 and bottomed at -$50.8 million in Q4 2021.
  • Average EBITDA over 5 years is -$16.7 million, with a median of -$16.3 million recorded in 2023.
  • The sharpest move saw EBITDA plummeted 131.87% in 2021, then soared 316.34% in 2025.
  • Year by year, EBITDA stood at -$50.8 million in 2021, then surged by 74.57% to -$12.9 million in 2022, then decreased by 3.48% to -$13.4 million in 2023, then soared by 61.68% to -$5.1 million in 2024, then skyrocketed by 316.34% to $11.1 million in 2025.
  • Business Quant data shows EBITDA for XERS at $11.1 million in Q4 2025, $620000.0 in Q3 2025, and -$1.9 million in Q2 2025.